首页 > 市场调查报告书 > 製药

孤儿药

市场调查报告书

商品编码

1529071

罕见疾病治疗市场- 按药物类型（生物製剂、非生物製剂）、治疗领域（癌症、呼吸系统疾病、心血管疾病）、患者（成人、儿童）、给药途径（口服、注射）-全球预测（ 2024 - 2032））

Rare Disease Treatment Market - By Drug Type (Biologics, Non-biologics), Therapeutic Area (Cancer, Respiratory Disorder, Cardiovascular Disorder), Patient (Adult, Pediatric), Route of Administration (Oral, Injectable) - Global Forecast (2024 - 2032)

出版日期: 2024年05月06日 | 出版商:

Global Market Insights Inc. | 英文 250 Pages | 商品交期: 2-3个工作天内

价格

简介目录

由于医学研究的进步以及强劲的生物製药投资，2024 年至 2032 年全球罕见疾病治疗市场的复合年增长率将达到 9%。基因疗法、精准医学和标靶治疗的突破正在重塑治疗方法。此外，生物製药领域的资金投入和合作的增加正在加速罕见疾病创新疗法的开发。这些努力增强了治疗选择并解决了未满足的医疗需求，创造了一个充满活力的市场环境，致力于改善全球罕见疾病患者的治疗结果和生活品质。

例如，2024 年 4 月，LifeArc 启动了 4000 万英镑的研究中心，旨在为患有罕见疾病的个体发现新的测试、治疗和治癒方法。透过促进测试、治疗和潜在治癒方法的创新，LifeArc 的计划有可能加速突破、改善患者的治疗效果并扩大全球范围内有效罕见疾病治疗的市场容量。

罕见疾病治疗行业根据药物类型、治疗领域、患者、给药途径和地区进行分类。

由于其功效和快速起效，注射剂细分市场将在 2024 年至 2032 年间显着成长。许多罕见疾病需要精确、有针对性的药物输送，而注射剂可以提供这种药物。与口服药物相比，该方法还确保了更高的生物利用度。通常透过注射给药的生物製剂和单株抗体的成长进一步推动了这一领域的发展。此外，注射技术的进步和慢性罕见疾病的日益普及也有助于注射剂市场的主导地位。

由于血友病、地中海贫血和镰状细胞性贫血等罕见血液疾病的高盛行率，到 2032 年，血液相关疾病领域将取得显着进展。这些疾病通常需要专门的长期治疗和管理，这推动了对创新疗法的需求。基因治疗、标靶治疗的进步和研究经费的增加促进了这一领域的成长。此外，认识的提高和诊断能力的提高确保了血液相关疾病仍然是罕见疾病治疗市场的一个重要焦点。

在医疗保健支出增加、患者人数增加和医疗保健基础设施改善的推动下，亚太地区将在 2024 年至 2032 年间获得大量市场份额。中国、日本和印度等国家正大力投资罕见疾病研究和治疗设施。此外，医疗保健专业人员和患者对罕见疾病的认识不断提高，也推动了该地区的市场成长。亚太地区对医学研究和创新进步的关键贡献将进一步巩固其作为罕见疾病治疗行业关键贡献者的角色。

产业生态系统分析
产业影响力
- 成长动力
  - 罕见疾病盛行率增加
  - 政府优惠政策
  - 新药上市数量不断增加
  - 增加新型治疗药物的研发活动
- 产业陷阱与挑战
  - 对罕见疾病治疗缺乏认识
  - 药物和治疗费用高
成长潜力分析
罕见疾病治疗的临床试验场景
管道分析
未来市场趋势
技术景观
流行病学情景
目前的疗法
报销场景
监管环境
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司矩阵分析
公司市占率分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按药物类型，2021 - 2032

主要趋势
生物製剂
非生物製品

第 6 章：市场估计与预测：按治疗领域，2021 - 2032 年

主要趋势
癌症
血液相关疾病
中枢神经系统
呼吸系统疾病
肌肉骨骼疾病
心血管疾病
其他治疗领域

第 7 章：市场估计与预测：按患者分类，2021 - 2032 年

主要趋势
成人
儿科

第 8 章：市场估计与预测：按管理途径，2021 - 2032 年

主要趋势
口服
可注射

第 9 章：市场估计与预测：按地区，2021 - 2032

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 波兰
- 瑞士
- 瑞典
- 欧洲其他地区
亚太地区
- 日本
- 中国
- 印度
- 澳洲
- 韩国
- 印尼
- 泰国
- 越南
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 智利
- 哥伦比亚
- 秘鲁
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 以色列
- 埃及
- 中东和非洲其他地区

第 10 章：公司简介

AbbVie Inc.
Alexion Pharmaceuticals, Inc.
Amgen Inc
AstraZeneca PLC
Baxter International
Bayer AG
Biogen
Bristol-Myers Squibb
Eli Lilly and Company
F. Hoffmann La Roche Ltd
GSK plc
Johnson & Johnson
Merck & Co. Inc.
Novartis AG
Novo Nordisk
Pfizer, Inc.
Pharmacyclics LLC
Sanofi SA
Seagen Inc.
Takeda Pharmaceutical Company Ltd.
Vertex Pharmaceutical Inc.

简介目录

Product Code: 3873

Global Rare Disease Treatment Market will reach a 9% CAGR from 2024 to 2032, attributed to advancements in medical research coupled with robust biopharmaceutical investments. Breakthroughs in gene therapies, precision medicine, and targeted treatments are reshaping therapeutic approaches. Moreover, increased funding and collaboration within the biopharmaceutical sector are accelerating the development of innovative therapies for rare diseases. These efforts enhance treatment options and address unmet medical needs, fostering a dynamic market environment focused on improving outcomes and quality of life for patients with rare diseases globally.

For instance, in April 2024, LifeArc initiated £40 million in research centers aimed at discovering novel tests, treatments, and cures for individuals affected by rare diseases. By fostering innovation in tests, treatments, and potential cures, LifeArc's initiative has the potential to accelerate breakthroughs, enhance patient outcomes, and expand the market's capacity for effective rare disease therapies on a global scale.

The rare disease treatment industry is classified based on drug type, therapeutic area, patient, route of administration, and region.

The injectable segment will see a notable surge between 2024 and 2032, owing to its efficacy and rapid onset of action. Many rare diseases require precise, targeted delivery of medication, which injectables provide. This method also ensures higher bioavailability compared to oral drugs. The rise in biologics and monoclonal antibodies, commonly administered via injection, further boosts this segment. Additionally, advancements in injection technologies and the growing prevalence of chronic rare diseases contribute to the injectable segment's market dominance.

The blood-related disorder segment will amass remarkable gains through 2032, propelled by the high prevalence of rare hematological conditions like hemophilia, thalassemia, and sickle cell anemia. These disorders often require specialized, long-term treatment and management, driving demand for innovative therapies. Advances in gene therapy, targeted treatments, and increasing research funding contribute to this segment's growth. Additionally, heightened awareness and improved diagnostic capabilities ensure that blood-related disorders remain a significant focus in the rare disease treatment market.

Asia Pacific will secure a substantial market presence from 2024 to 2032, driven by rising healthcare spending, expanding patient populations, and improving healthcare infrastructure. Countries like China, Japan, and India are investing heavily in rare disease research and treatment facilities. Additionally, increasing awareness among healthcare professionals and patients about rare diseases is boosting market growth in the region. Asia Pacific's pivotal contribution to advancements in medical research and innovation will further solidify its role as a key contributor to the rare disease treatment industry.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increase in the prevalence of rare diseases
  - 3.2.1.2 Favorable government policies
  - 3.2.1.3 Growing number of new drug launches
  - 3.2.1.4 Increasing R&D activities for novel therapeutics drugs
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Lack of awareness regarding rare disease treatment
  - 3.2.2.2 High cost of the drugs and therapy
3.3 Growth potential analysis
3.4 Clinical trial scenario for rare disease treatment
3.5 Pipeline analysis
3.6 Future market trends
3.7 Technology landscape
3.8 Epidemiology scenario
3.9 Current therapies
3.10 Reimbursement scenario
3.11 Regulatory landscape
3.12 Porter's analysis
3.13 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Biologics
5.3 Non-biologics

Chapter 6 Market Estimates and Forecast, By Therapeutic Area, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Cancer
6.3 Blood-related disorders
6.4 Central nervous system
6.5 Respiratory disorders
6.6 Musculoskeletal disorders
6.7 Cardiovascular disorders
6.8 Other therapeutic areas

Chapter 7 Market Estimates and Forecast, By Patient, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Adult
7.3 Pediatric

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Oral
8.3 Injectable

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Poland
- 9.3.7 Switzerland
- 9.3.8 Sweden
- 9.3.9 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Indonesia
- 9.4.7 Thailand
- 9.4.8 Vietnam
- 9.4.9 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Chile
- 9.5.5 Colombia
- 9.5.6 Peru
- 9.5.7 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Israel
- 9.6.5 Egypt
- 9.6.6 Rest of Middle East and Africa